Source - View Current Issue (VOL. 7 NO. 6 JUNE 2013): PDF | Interactive Version
GI & Hepatology News is the official newspaper of the AGA Institute and provides the gastroenterologist with timely and relevant news and commentary about clinical developments and about the impact of health-care policy. The newspaper is led by an internationally renowned board of editors.
Risk of hepatitis C
transmission low in
longtime couples
BY MICHELE G. SULLIVAN
IMNG Medical News
Heterosexual partners rarely infected.
The risk of sexually
transmitting a chronic
hepatitis C infection to
a long-term monogamous
heterosexual partner is very
low, averaging just about
1% per year.
That risk level works out
to a transmission rate of
about one in every 190,000
sexual contacts, Dr. Norah
Terrault and her colleagues
reported in Hepatology
(2013;57:881-9).
The cross-sectional study
also found that no one sexual practice – including
anal intercourse or inter-
course during menses –
significantly increased the
risk of transmission, wrote
Dr. Terrault of the University of California, San
Francisco.
The findings
can be used to provide
“unambiguous and reassuring counseling messages,” she and her
coinvestigators noted.
The study included 500
subjects with chronic HCV
infections, and their sexual
partners. All couples reported longtime, monogamous
relationships (median duration, 15 years); the relation-
ship duration varied widely,
spanning 2-52 years.
Each of the partners was
interviewed separately
about their sexual contacts and practices.
At the time of inter-
view, the index subjects were a median of 49 years old and the partners, a
median of 48 years.
The HCV-positive subjects reported the highest incidence of past risk
factors, including blood transfusions
before 1992 (32%), injected illegal
drugs (54%), and being stuck by a
sharp bloody item in a hospital (4%).
Nearly half (46%) reported having
had at least 20 lifetime sexual partners, with 21% having had 50 or
more.
However, partners also reported
some risk factors: 11% had an early
transfusion, 2% used illegal drugs,
and 2% had a hospital sharps incident. Many (27%) also reported having had at least 20 sexual partners.
Among the 500 couples, 20 partners (4%) were coinfected with HCV.
Of these, nine were concordantly infected, eight discordantly, and three
were indeterminate.
Six of the concordant couples under went phylogenetic typing. Three
were infected with the same HCV
isolate and three with different
strains.
The investigators estimated
the time of transmission and any additional risk factor among the three
couples with concordant strains.
For the first couple, with an 18-
year relationship, transmission probably occurred after about 6.5 years.
The female had a history of injected
drug use, while the male had no
identifiable risk factors.
The second couple had a 28-year
relationship; transmission probably
occurred at around 15 years. “The female partner had a history of injectable drug use and both partners
reported more than 20 prior sexual
partners, a history of sexual trans-
mitted diseases, and a history of
snorting of drugs.”
For the third couple, who had
been together for 10 years, transmission probably occurred around year
6. “The male partner had a history
of injectable drug use, of being
stuck by a sharp bloody object while
working in a hospital, and more than
20 prior sexual partners; both partners reported snorting drugs and
sharing snorting equipment.”
The investigators determined that
these infections were probably sexually transmitted between partners – a
prevalence of about 1%. “The estimated risk per sexual contact ranged
from 1/380,000 to 1/190, 000,” they
said. They didn’t identify behaviors that significantly increased the risk of
transmission.
Coinfected couples
were more likely to have vaginal intercourse during menses (100% vs.
66%), more likely to have anal inter-
course (67% vs. 30%), and less likely
to use condoms (0% vs. 30%), but
none of these differences was statistically significant.
“Our results ... support the current
national recommendations that couples not change their sexual practices
if they are in a monogamous hetero-
sexual relationship.”
None of the study authors reported any financial conflicts
http://www.gastro.org/journals-publications/gi-hepatology-news/GI_-_Hepatology_News_-_June_2013.pdf
Read breaking new s stories now : visit the GI & Hepatology News website.
This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
- Home
- Newly Diagnosed With Hep C? Or Considering Treatment?
- All FDA Approved Drugs To Treat Hepatitis C
- Hepatitis C Genotypes and Treatment
- Mavyret (glecaprevir/pibrentasvir)
- Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Zepatier(Elbasvir/Grazoprevir)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- HCV Liver Fibrosis
- FibroScan® Understanding The Results
- HCV Cirrhosis
- Staging Cirrhosis
- HCV Liver Cancer
- Risk Of Developing Liver Cancer After HCV Treatment
- Treating Elderly HCV Patients
- Fatty Liver Disease: NAFLD/NASH
- Current research articles on ailments that may be related to HCV
- Is There A Natural Way To Improve Liver Fibrosis?
- Can Food Or Herbs Interact With Conventional Medical Treatments?
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment